Commentary

Video

Optimal Management Strategies in Advanced HER2+ Breast Cancer

Author(s):

Joyce A. O'Shaughnessy, MD,Neil M. Iyengar, MD

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the various management strategies for treatment of patients with advanced or metastatic HER2-positive breast cancer.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing [email protected], or by calling 833-315-2722.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
View More
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Related Content
HR+/HER2– Early Breast Cancer | Image Credit: © Axel Kock - stock.adobe.com
June 19th 2025

Health Canada Approves Adjuvant Ribociclib for HR+/HER2– Early Breast Cancer

Kate Gasparini, PharmD, BCOP, BCPPS, pediatric oncology clinical pharmacy specialist, Memorial Sloan Kettering Cancer Center
June 17th 2025

Liquid Imatinib Formulation Expands Leukemia Treatment Options and Improves Treatment Adherence: With Kate Gasparini, PharmD, BCOP, BCPPS

FDA
June 12th 2025

FDA Grants Fast Track Designation to RAD101 for Imaging of Brain Metastases

Michael J. Mauro, MD, attending physician, Memorial Sloan Kettering Cancer Center
May 19th 2025

Updated Nilotinib Formulation Improves Treatment Adherence in Ph+ CML: With Michael J. Mauro, MD

Sarah Sammons, MD
June 10th 2025

RLY-2608 Plus Fulvestrant Demonstrates Efficacy in PIK3CA-Mutated, HR+/HER2– Advanced Breast Cancer

Elacestrant Combinations in ER+ Breast Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
June 10th 2025

Elacestrant Displays Potential as Combination Backbone in ER+ Breast Cancer After CDK4/6 Inhibition